254 related articles for article (PubMed ID: 30651183)
21. Pharmacist Presence Decreases Time to Prothrombin Complex Concentrate in Emergency Department Patients with Life-Threatening Bleeding and Urgent Procedures.
Masic D; Hidalgo DC; Kuhrau S; Chaney W; Rech MA
J Emerg Med; 2019 Nov; 57(5):620-628. PubMed ID: 31447188
[TBL] [Abstract][Full Text] [Related]
22. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
[TBL] [Abstract][Full Text] [Related]
23. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
[TBL] [Abstract][Full Text] [Related]
24. Combination Therapy Using Prothrombin Complex Concentrate and Vitamin K in Anticoagulated Patients with Traumatic Intracranial Hemorrhage Prevents Progressive Hemorrhagic Injury: A Historically Controlled Study.
Koyama H; Yagi K; Hara K; Matsubara S; Tao Y; Uno M
Neurol Med Chir (Tokyo); 2021 Jan; 61(1):47-54. PubMed ID: 33208582
[TBL] [Abstract][Full Text] [Related]
25. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
27. Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.
Cascone AE; Daley MJ; Pan N; Padilla-Tolentino E; Milling TJ
Pharmacotherapy; 2021 Jun; 41(6):501-507. PubMed ID: 33866591
[TBL] [Abstract][Full Text] [Related]
28. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Panos NG; Cook AM; John S; Jones GM;
Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
[TBL] [Abstract][Full Text] [Related]
29. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
[TBL] [Abstract][Full Text] [Related]
30. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery.
Schmidt LE; Hinton MS; Martin ND
J Pharm Pract; 2024 Feb; 37(1):74-79. PubMed ID: 36083782
[No Abstract] [Full Text] [Related]
31. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
Reynolds TR; Gilbert BW; Hall KM
J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
[TBL] [Abstract][Full Text] [Related]
32. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
[TBL] [Abstract][Full Text] [Related]
33. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
[TBL] [Abstract][Full Text] [Related]
34. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
[TBL] [Abstract][Full Text] [Related]
35. Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage.
Fischer D; Sorensen J; Fontaine GV
Neurocrit Care; 2018 Feb; 28(1):43-50. PubMed ID: 28612131
[TBL] [Abstract][Full Text] [Related]
36. Prothrombin complex concentrate for vitamin K antagonist reversal in traumatic intracranial hemorrhage.
Beynon C; Nofal M; Rizos T; Laible M; Sakowitz OW; Unterberg AW
J Clin Neurosci; 2020 Sep; 79():197-202. PubMed ID: 33070895
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
38. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries.
Sadek E; Curtiss W; Andrews J; Hecht J
Emerg Med J; 2024 Feb; 41(3):162-167. PubMed ID: 38267194
[TBL] [Abstract][Full Text] [Related]
39. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
40. Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors.
Hormese M; Littler A; Doane B; Glowacki N; Khimani A; Vivacqua N; Rudenberg K
J Thromb Thrombolysis; 2021 Oct; 52(3):828-835. PubMed ID: 33725284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
